What is it worth?What's a fair value for AEZS's assets? C$100 million? $150 million? CZO shareholders get 50% of those assets. 50% of C$100-C$150 million is C$50-C$75 million. With the consolidated asset base and North American and European footprint the company is also positioned to execute much stronger deals.
AEZS's assets: What are they worth?
- $50 million cash.
- ~C$113.4 million in tax loss carryforwards.
- Diagnostic test potentially approved in 2024 that Novo Nordisk spent ~C$250 million(cash, equity) on plus royalties. The pediatric population is the most important and the test could be approved for children in 2024. AEZS is in talks concerning relicensing to a new partner.
- Preclinical pipeline. Many preclinical assets have been valued below cash but we may now be before a new bull market as AEZS's preclinical assets near the clinic.